CH680983A5 - - Google Patents
Download PDFInfo
- Publication number
- CH680983A5 CH680983A5 CH2906/90A CH290690A CH680983A5 CH 680983 A5 CH680983 A5 CH 680983A5 CH 2906/90 A CH2906/90 A CH 2906/90A CH 290690 A CH290690 A CH 290690A CH 680983 A5 CH680983 A5 CH 680983A5
- Authority
- CH
- Switzerland
- Prior art keywords
- salmeterol
- fluticasone propionate
- inhalation
- inhaler
- treatment
- Prior art date
Links
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229960004017 salmeterol Drugs 0.000 claims abstract description 26
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims abstract description 23
- 229960000289 fluticasone propionate Drugs 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 11
- SJJCQDRGABAVBB-UHFFFAOYSA-M 1-hydroxy-2-naphthoate Chemical compound C1=CC=C2C(O)=C(C([O-])=O)C=CC2=C1 SJJCQDRGABAVBB-UHFFFAOYSA-M 0.000 claims description 3
- 229940071648 metered dose inhaler Drugs 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229940021597 salmeterol and fluticasone Drugs 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 description 15
- 208000006673 asthma Diseases 0.000 description 13
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 9
- 229940029284 trichlorofluoromethane Drugs 0.000 description 9
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 8
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 8
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 7
- 229940124630 bronchodilator Drugs 0.000 description 6
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229960002052 salbutamol Drugs 0.000 description 5
- 230000000087 stabilizing effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000024696 nocturnal asthma Diseases 0.000 description 4
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229950000210 beclometasone dipropionate Drugs 0.000 description 2
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 2
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BOSAWIQFTJIYIS-UHFFFAOYSA-N 1,1,1-trichloro-2,2,2-trifluoroethane Chemical compound FC(F)(F)C(Cl)(Cl)Cl BOSAWIQFTJIYIS-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-M 4-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-M 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 201000010659 intrinsic asthma Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940125386 long-acting bronchodilator Drugs 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- PDEFQWNXOUGDJR-UHFFFAOYSA-M sodium;2,2-dichloropropanoate Chemical compound [Na+].CC(Cl)(Cl)C([O-])=O PDEFQWNXOUGDJR-UHFFFAOYSA-M 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- KQTIIICEAUMSDG-UHFFFAOYSA-N tricarballylic acid Chemical compound OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB898920392A GB8920392D0 (en) | 1989-09-08 | 1989-09-08 | Medicaments |
| GB898923644A GB8923644D0 (en) | 1989-10-20 | 1989-10-20 | Medicaments |
| SG166294A SG166294G (en) | 1989-09-08 | 1994-11-18 | Inhalation medicaments for treating respiratory disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| CH680983A5 true CH680983A5 (forum.php) | 1992-12-31 |
| CH680983C1 CH680983C1 (forum.php) | 2008-06-25 |
| CH680983C9 CH680983C9 (forum.php) | 2008-08-15 |
Family
ID=27264677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH2906/90A CH680983C9 (forum.php) | 1989-09-08 | 1990-09-07 |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0416951B1 (forum.php) |
| JP (1) | JP3042867B2 (forum.php) |
| AT (1) | ATE99941T1 (forum.php) |
| BE (1) | BE1003053A3 (forum.php) |
| CA (1) | CA2024916C (forum.php) |
| CH (1) | CH680983C9 (forum.php) |
| DE (2) | DE19975040I2 (forum.php) |
| DK (1) | DK0416951T3 (forum.php) |
| ES (1) | ES2062392T3 (forum.php) |
| FR (1) | FR2651677B1 (forum.php) |
| HK (1) | HK18695A (forum.php) |
| HU (1) | HU211272A9 (forum.php) |
| IE (1) | IE65535B1 (forum.php) |
| IL (1) | IL95590A (forum.php) |
| IT (1) | IT1241996B (forum.php) |
| LU (1) | LU90392I2 (forum.php) |
| NL (1) | NL990012I2 (forum.php) |
| NZ (1) | NZ235221A (forum.php) |
| PH (1) | PH27594A (forum.php) |
| SG (1) | SG166294G (forum.php) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270305A (en) | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
| IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| CZ288032B6 (cs) * | 1991-12-18 | 2001-04-11 | Aktiebolaget Astra | Farmaceutický prostředek pro podání inhalací |
| SE9703407D0 (sv) | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| DE59914603D1 (de) | 1998-11-13 | 2008-02-14 | Jagotec Ag | Multidosis-Trockenpulverinhalator mit Pulverreservoir |
| GB9903759D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| GB9904919D0 (en) | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
| ES2274803T3 (es) | 1999-09-11 | 2007-06-01 | Glaxo Group Limited | Formulacion farmaceutica de propionato de fluticasona. |
| ES2238334T3 (es) * | 1999-12-24 | 2005-09-01 | Glaxo Group Limited | Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona. |
| US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| KR100889426B1 (ko) | 2000-08-05 | 2009-03-23 | 글락소 그룹 리미티드 | 항염증제로서의 6.알파.,9.알파.-디플루오로-17.알파.-'(2-푸라닐카르복실)옥시-11.베타.-히드록시-16.알파.-메틸-3-옥소-안드로스트-1,4-디엔-17-카르보티오산 ｓ-플루오로메틸 에스테르 |
| FI20002215A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
| FI20002216A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit astman hoitoon |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| ATE365720T1 (de) | 2001-03-08 | 2007-07-15 | Glaxo Group Ltd | Agonisten von beta-adrenorezeptoren |
| DE60224172T2 (de) | 2001-03-22 | 2008-12-04 | Glaxo Group Ltd., Greenford | Formanilid-derivative als beta2-adrenorezeptor-agonisten |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| NZ528888A (en) | 2001-04-30 | 2005-10-28 | Glaxo Group Ltd | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
| CN101701006B (zh) | 2001-09-14 | 2014-03-05 | 葛兰素集团有限公司 | 治疗呼吸疾病的苯乙醇胺衍生物 |
| US7258118B2 (en) | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
| DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
| ES2305438T5 (es) † | 2002-02-04 | 2012-06-05 | Glaxo Group Limited | Formulación para inhalación que comprende un glucocorticoide y un agonista del ?2-adreno-receptor. |
| EP1757281A3 (en) * | 2002-02-04 | 2009-07-15 | Glaxo Group Limited | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
| JP2005519110A (ja) * | 2002-03-04 | 2005-06-30 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規なケイ皮酸塩、その調製方法及び医薬品としての使用 |
| GB0208609D0 (en) * | 2002-04-13 | 2002-05-22 | Glaxo Group Ltd | Compositions |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| US7879833B2 (en) | 2002-12-12 | 2011-02-01 | Nycomed Gmbh | Combination medicament |
| GB0303396D0 (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
| SE527069C2 (sv) | 2003-06-19 | 2005-12-13 | Mederio Ag | Förfarande och anordning för administrering av läkemedelspulver |
| DK1658063T3 (da) | 2003-08-06 | 2014-05-12 | Galephar M F | Fordelagtige kombinationer til inhalering af nacystelyn og bronkodilatorer |
| WO2005087192A2 (en) * | 2004-03-12 | 2005-09-22 | Cipla Limited | Salmeterol inhalation formulations |
| JP4621736B2 (ja) | 2004-07-16 | 2011-01-26 | アルミラル ソシエダツド アノニマ | 粉末薬剤を投与するための吸入器、及びこの吸入器と共に使用するための粉末カートリッジシステム |
| RU2456027C2 (ru) | 2006-12-22 | 2012-07-20 | Альмираль, С.А. | Ингаляционное устройство для медикаментов в порошковой форме |
| CN101744792B (zh) * | 2008-12-17 | 2013-04-17 | 张凯 | 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺 |
| RU2713404C2 (ru) | 2009-05-29 | 2020-02-05 | Перл Терапьютикс, Инк. | Композиции для легочной доставки антагонистов мускариновых рецепторов длительного действия и агонистов в2-адренергических рецепторов длительного действия и связанные с ними способы и системы |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| ES2712988T5 (es) | 2013-03-15 | 2022-10-21 | Pearl Therapeutics Inc | Métodos y sistemas para acondicionamiento de materiales cristalinos en partículas |
| KR20160003183A (ko) * | 2013-04-29 | 2016-01-08 | 사노피 에스에이 | 흡입식 약학적 조성물 및 그를 포함하는 흡입기 장치 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2107715B (en) * | 1981-10-19 | 1985-11-13 | Glaxo Group Ltd | Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it |
| ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| FR2588474B1 (fr) * | 1985-10-16 | 1987-11-27 | Cird | Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste |
-
1990
- 1990-09-05 IL IL9559090A patent/IL95590A/en not_active IP Right Cessation
- 1990-09-07 CH CH2906/90A patent/CH680983C9/de not_active IP Right Cessation
- 1990-09-07 AT AT90309846T patent/ATE99941T1/de active
- 1990-09-07 BE BE9000862A patent/BE1003053A3/fr not_active IP Right Cessation
- 1990-09-07 CA CA002024916A patent/CA2024916C/en not_active Expired - Lifetime
- 1990-09-07 DE DE1990605951 patent/DE19975040I2/de active Active
- 1990-09-07 ES ES90309846T patent/ES2062392T3/es not_active Expired - Lifetime
- 1990-09-07 JP JP2235997A patent/JP3042867B2/ja not_active Expired - Lifetime
- 1990-09-07 FR FR909011142A patent/FR2651677B1/fr not_active Expired - Lifetime
- 1990-09-07 PH PH41153A patent/PH27594A/en unknown
- 1990-09-07 EP EP90309846A patent/EP0416951B1/en not_active Expired - Lifetime
- 1990-09-07 DK DK90309846.5T patent/DK0416951T3/da active
- 1990-09-07 IE IE325690A patent/IE65535B1/en not_active IP Right Cessation
- 1990-09-07 DE DE69005951T patent/DE69005951T2/de not_active Expired - Lifetime
- 1990-09-07 IT IT48260A patent/IT1241996B/it active Protection Beyond IP Right Term
- 1990-09-07 NZ NZ235221A patent/NZ235221A/en unknown
-
1994
- 1994-11-18 SG SG166294A patent/SG166294G/en unknown
-
1995
- 1995-02-09 HK HK18695A patent/HK18695A/xx not_active IP Right Cessation
- 1995-06-02 HU HU95P/P00150P patent/HU211272A9/hu unknown
-
1999
- 1999-04-14 NL NL990012C patent/NL990012I2/nl unknown
- 1999-04-26 LU LU90392C patent/LU90392I2/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP3042867B2 (ja) | 2000-05-22 |
| EP0416951B1 (en) | 1994-01-12 |
| IT1241996B (it) | 1994-02-02 |
| DE19975040I2 (de) | 2006-07-13 |
| IL95590A (en) | 1996-06-18 |
| LU90392I2 (fr) | 1999-06-28 |
| ES2062392T3 (es) | 1994-12-16 |
| IT9048260A1 (it) | 1992-03-07 |
| JPH03167120A (ja) | 1991-07-19 |
| CA2024916C (en) | 2002-07-09 |
| NZ235221A (en) | 1992-11-25 |
| NL990012I1 (nl) | 1999-07-01 |
| FR2651677A1 (fr) | 1991-03-15 |
| DK0416951T3 (da) | 1994-02-14 |
| CH680983C1 (forum.php) | 2008-06-25 |
| BE1003053A3 (fr) | 1991-11-05 |
| DE69005951D1 (de) | 1994-02-24 |
| FR2651677B1 (fr) | 1993-08-06 |
| IE903256A1 (en) | 1991-03-13 |
| CH680983C9 (forum.php) | 2008-08-15 |
| DE69005951T2 (de) | 1994-05-26 |
| IL95590A0 (en) | 1991-09-16 |
| IE65535B1 (en) | 1995-11-01 |
| NL990012I2 (nl) | 1999-09-01 |
| CA2024916A1 (en) | 1991-03-09 |
| IT9048260A0 (it) | 1990-09-07 |
| HU211272A9 (en) | 1995-11-28 |
| EP0416951A1 (en) | 1991-03-13 |
| HK18695A (en) | 1995-02-17 |
| PH27594A (en) | 1993-08-31 |
| ATE99941T1 (de) | 1994-01-15 |
| SG166294G (en) | 1995-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH680983A5 (forum.php) | ||
| KR100234864B1 (ko) | 기도 및 폐질환을 치료하기 위한 모메타손푸로에이트 약제 | |
| RU2327450C2 (ru) | Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды | |
| JP6941224B2 (ja) | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 | |
| FR2651678A1 (fr) | Composition pharmaceutique a base de salmeterol et de dipropionate de beclometasone. | |
| CA2123909C (en) | New combination of formoterol and budesonide | |
| AU777827B2 (en) | Aerosol formulations and devices for increasing libido in women via acute testosterone administration | |
| JP2001513106A (ja) | グルココルチコイドと局所麻酔剤との相乗的な併用による好酸球関連病態、例えば気管支喘息の治療 | |
| JPH0597707A (ja) | ベータ−２−気管支拡張薬の改善使用 | |
| TW200524615A (en) | Aqueous suspensions of ciclesonide for nebulisation | |
| CA2811345C (en) | Compound composition for inhalation used for treating asthma | |
| WO1996037198A1 (de) | Inhalative verwendung von antidepressiva zur behandlung von asthma | |
| GB2235627A (en) | Inhalation medicaments | |
| EP4169511A1 (en) | Intranasal epinephrine formulations and methods for the treatment of disease | |
| US7521438B1 (en) | Combination of loteprednol and β2-adrenoceptor agonists | |
| US20090118249A1 (en) | Dheas inhalation compositions | |
| EP0613371A1 (en) | New combination of formoterol and budesonide | |
| EP1957121B1 (en) | Acute treatment of social phobia with an androsta-4,16-dien-3-ol steroid | |
| JP2012067072A (ja) | ぜんそくの投与に用いられる吸入性複方組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCF | Supplementary protection certificate filed |
Free format text: OICM-NO 54975/19990329, 19990602 |
|
| SPCG | Supplementary protection certificate granted |
Free format text: OICM-NO 54975/19990329, 19990602, EXPIRES:20140329 |
|
| SPCN | Certificates - modification new representative |
Spc suppl protection certif: C680983/01 Representative=s name: BRAUNPAT BRAUN EDER AG, CH |
|
| NV | New agent | ||
| PFA | Name/firm changed |
Owner name: GLAXO GROUP LIMITED Free format text: GLAXO GROUP LIMITED#6-12 CLARGES STREET#LONDON W1Y 8DH (GB) $ ISLER & PEDRAZZINI AG#POSTFACH 1772#8027 ZUERICH (CH) -TRANSFER TO- GLAXO GROUP LIMITED#GLAXO WELLCOME HOUSE, BERKELEY AVENUE#GREENFORD (MIDDX UB6 0NN) (GB) $ ISLER & PEDRAZZINI AG#POSTFACH 1772#8027 ZUERICH (CH) |
|
| PK | Correction |
Free format text: LE MANDATAIRE A ETE MENTIONNE PAR ERREUR COMME TITULAIRE. |
|
| AEN | Scope or validity of the patent modified |
Free format text: DECLARATION DE RENONCIATION PUBLIEE: 25.06.2008 |
|
| PK | Correction |
Free format text: INHABER + VERTRETER KORRIGIERT. |
|
| PL | Patent ceased | ||
| SPCP | Certificates - modification of firm |
Owner name: GLAXO GROUP LIMITED, GB Spc suppl protection certif: C680983/01 |
|
| SPCL | Supplementary protection certificate deletion |
Spc suppl protection certif: C680983/01 |